App-Quantinova.ai

Wearable sensor motor outcomes across patients with Parkinson’s disease from Asian, Black, and Caucasian ethnicity in the United Kingdom

D. van Wamelen - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

N/A

What do medical students know about dystonia? Results before and after a brief educational intervention.

S. Khan - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Dystonia

N/A

Are two too many when it comes to the treatment of anal canal cancer with concurrent radiation and mitomycin C?

Zainab Al Habsi - American Society of Clinical Oncology (ASCO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

mitomycin

Prognostic impact of early treatment discontinuation and early oxaliplatin discontinuation in patients treated with 6 months of oxaliplatin-based adjuvant chemotherapy for stage III colon cancer: an ACCENT/IDEA pooled analysis of 11 trials.

Claire Gallois - American Society of Clinical Oncology (ASCO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Colorectal Cancer

Oxaliplatin

Incomplete preoperative staging results in suboptimal treatment in rectal cancer patients: A population-based study.

Sunil Patel - American Society of Clinical Oncology (ASCO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Colorectal Cancer

STD12

The association between preoperative CEA, the systemic inflammatory response and survival in colon cancer.

Allan Matthew Golder - American Society of Clinical Oncology (ASCO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Colorectal Cancer

N/A

Combining the quantitative fecal immunochemical test and full blood count to rule out colorectal cancer in a symptomatic patient referral pathway.

Mark Johnstone - American Society of Clinical Oncology (ASCO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Colorectal Cancer

N/A

Comparative analysis of overall survival in patients with HER2-amplified treatment-refractory metastatic colorectal cancer treated with pertuzumab plus trastuzumab in Mypathway and patients treated in the real-world.

Takuya Yoshimoto - American Society of Clinical Oncology (ASCO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Colorectal Cancer

Trastuzumab

Real-world experience of pembrolizumab in microsatellite instability-high CRC: A Scottish multicenter analysis.

Aisha Ghaus - American Society of Clinical Oncology (ASCO) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

Pembrolizumab

Baseline treatment patterns of the first 277 patients in PROMETCO: A real-world, prospective, longitudinal cohort study on the continuum of care in metastatic colorectal cancer (mCRC).

Jean-Baptiste Bachet - American Society of Clinical Oncology (ASCO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Colorectal Cancer

N/A

Investigating the prognostic value of TP53 and PIK3CA mutations in metastatic colorectal cancer (mCRC): Applying Structured Query Language (SQL) algorithms to real-world data from a high-volume U.K. tertiary cancer center.

Caroline Fong - American Society of Clinical Oncology (ASCO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Colorectal Cancer

TP53

Preferences for colorectal cancer screening of physicians and individuals at average risk in the United States: A discrete choice experiment.

Sebastian Heidenreich - American Society of Clinical Oncology (ASCO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Colorectal Cancer

N/A

Cardiac toxicities of fluoropyrimidine chemotherapy: A literature review and evaluation of current practice at a large U.K. cancer center.

Christopher Williams - American Society of Clinical Oncology (ASCO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Cardiotoxicity

Fluorouracil

Trajectories of body weight change and survival among mCRC patients treated with systemic therapy: Pooled analysis from the ARCAD database.

Jan Franko - American Society of Clinical Oncology (ASCO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Colorectal Cancer

Bevacizumab

AB1, a novel protein targeting TP53 mutated GI tumors.

Agamemnon A. Epenetos - American Society of Clinical Oncology (ASCO) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

TP53

Improved organ preservation with dose escalation using contact X-ray brachytherapy for good responders following external beam chemoradiotherapy: Long-term outcomes from a single institution.

Arthur Sun Myint - American Society of Clinical Oncology (ASCO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Colorectal Cancer

Capecitabine

BREAKWATER safety lead-in (SLI): Encorafenib + cetuximab (EC) ± chemotherapy for first-line (1L) treatment (tx) of BRAF V600E-mutant (BRAFV600E) metastatic colorectal cancer (mCRC).

Scott Kopetz - American Society of Clinical Oncology (ASCO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Colorectal Cancer

Encorafenib

The association between tumour sidedness, clinicopathological characteristics and outcomes in patients undergoing curative resection for colon cancer.

Allan Matthew Golder - American Society of Clinical Oncology (ASCO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Colorectal Cancer

N/A

Serial sampling of rectal tumors during radiotherapy: A proof-of-concept study.

Leia Jones - American Society of Clinical Oncology (ASCO) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

Interferon Gamma

Evaluation of baseline BRAF V600E mutation in circulating tumor DNA and efficacy response from the BEACON study.

Scott Kopetz - American Society of Clinical Oncology (ASCO) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

Binimetinib

Filters

45280 Abstracts